Zoster (Shingles) ACIP Vaccine Recommendations
Advisory Committee on Immunization Practices (ACIP)
Published in Morbidity and Mortality Weekly Report (MMWR)
The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CDC Director and, if adopted, are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).
- Anderson TC, Masters NB, Guo A, et al. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR. 2022;71(3):80–84.
- Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR 2018;67:103–108.
- Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of Herpes Zoster. MMWR 2008;57(5):1-30.
For your convenience, these archived publications can be used for historical and research purposes.
- MMWR, August 22, 2014, Vol 63, #33
Update on Recommendations for Use of Herpes Zoster Vaccine
Print version [20 pages]
- MMWR, November 11, 2011, Vol 60, #44
Update on Herpes Zoster Vaccine: Licensure for Persons Aged 50 Through 59 Years
Print version [1.32MB, 36 pages]
Note: A shingles vaccine called zoster vaccine live (Zostavax) is no longer available for use in the United States, as of November 18, 2020.